Canadian-based cancer therapies developer DelMar Pharmaceuticals is set to initiate a Phase III STAR-3 clinical trial of VAL-083 for the treatment of patients with refractory glioblastoma multiforme (GBM), following the approval from Institutional Review Board (IRB).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

VAL-083 (dianhydrogalactitol) is an investigational DNA-targeting agent currently being developed to introduce interstrand DNA cross-links at guanine’s N7-position, resulting in the breakage of DNA’s double-strand and cancer cell death.

The randomised, controlled, adaptive design STAR-3 trial will include approximately 180 patients who had experienced disease progression after therapy with temozolomide and bevacizumab. 

Designed to be conducted at 25 US sites, the trial will involve administration of 40mg/m² intravenous VAL-083 in around 120 subjects on days one, two and three of a 21-day regimen, while up to 60 volunteers will be given temozolomide, lomustine or carboplatin.

DelMar Pharmaceuticals chairman and CEO Jeffrey Bacha said: "We are pleased to remain on track to open enrolment in this trial at leading centres in the US. 

"Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options."

“Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options." 

With the primary endpoint as overall survival, the trial will include evaluation of safety and laboratory factors such as interval medical histories, targeted physical exams, neurologic evaluations and complete blood counts for every 21 days during the treatment period.

According to the data from the previous Phase I and II trials, VAL-083 indicated clinically meaningful survival benefit for recurrent GBM patients after treatment with temozolomide and bevacizumab.

VAL-083 is currently being studied in several other trials for different lines of GBM therapy.


Image: MR of glioblastoma. Photo: courtesy of Christaras A.